Teva Pharmaceuticals Announces Appointment of Dr. Arie Belldegrun to Board
of Directors
Business Wire
JERUSALEM -- February 11, 2013
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that Dr. Arie
Belldegrun was appointed by the Board of Directors of Teva, at its meeting of
February 5, 2013, to fill a vacancy on the Board effective immediately. Dr.
Belldegrun's term of office will extend until Teva’s 2013 Annual Meeting of
Shareholders.
“We are pleased to welcome Dr. Belldegrun to our Board. Arie’s extensive
experience in the pharmaceutical industry both as a doctor, a business leader
and an academic will enable him to make significant contributions to the Board
immediately and help guide us as we look for new and innovative ways to bring
medicines to patients around the world and continue to increase value for our
shareholders,” stated Dr. Phillip Frost, Chairman of the Board, Teva
Pharmaceutical Industries Ltd.
Dr. Belldegrun is a director of the UCLA Institute of Urologic Oncology and
Professor and Chair of Urologic Oncology at the David Geffen School of
Medicine at the University of California, Los Angeles. Dr. Belldegrun serves
as the Chairman of the Board of Kite Pharma, Inc., Arno Therapeutics Inc., and
TheraCoat, Ltd.
Dr. Belldegrun received his medical degree at the Hadassah Medical School of
the Hebrew University and conducted his post-doctoral studies at the Weizmann
Institute of Science in Israel. He completed his residency in urologic surgery
at Harvard Medical School and his surgical oncology fellowship at the National
Cancer Institute (NCI) / National Institute of Health (NIH).
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic drugs as
well as innovative and specialty pharmaceuticals and active pharmaceutical
ingredients. Headquartered in Israel, Teva is the world's leading generic drug
maker, with a global product portfolio of more than 1,000 molecules and a
direct presence in about 60 countries. Teva's branded businesses focus on CNS,
oncology, pain, respiratory and women's health therapeutic areas as well as
biologics. Teva currently employs approximately 46,000 people around the world
and reached $18.3 billion in net revenues in 2011.
Teva's Safe Harbor Statement under the U. S. Private Securities Litigation
Reform Act of 1995:
This release contains forward-looking statements, which express the current
beliefs and expectations of management. Such statements are based on
management’s current beliefs and expectations and involve a number of known
and unknown risks and uncertainties that could cause our future results,
performance or achievements to differ significantly from the results,
performance or achievements expressed or implied by such forward-looking
statements, including statements relating to the results of the GALA phase III
trial and the potential efficacy or future market or marketability of
glatiramer acetate 40 mg/1 ml. Following further analysis, Teva's
interpretation of the results could differ materially depending on a number of
factors, and we caution investors not to place undue reliance on the
forward-looking statements contained in this press release as there can be no
guarantee that the results from the phase III trial discussed in this press
release will be confirmed upon full analysis of the results of the trial and
additional information relating to the safety, efficacy or tolerability of
glatiramer acetate 40 mg/1 ml may be discovered upon further analysis of data
from the phase III trial. Even if the results described in this release are
confirmed upon full analysis of the GALA study, we cannot guarantee that
glatiramer acetate 40 mg/1 ml will be approved for marketing in a timely
manner, if at all, by regulatory authorities in the EU or in the U.S.
Important factors that could cause or contribute to such differences include
risks relating to: our ability to develop and commercialize additional
pharmaceutical products, competition for our innovative products, especially
Copaxone® (including competition from innovative orally-administered
alternatives, as well as from potential generic equivalents), competition for
our generic products (including from other pharmaceutical companies and as a
result of increased governmental pricing pressures), competition for our
specialty pharmaceutical businesses, our ability to achieve expected results
through our innovative R&D efforts, the effectiveness of our patents and other
protections for innovative products, decreasing opportunities to obtain U.S.
market exclusivity for significant new generic products, our ability to
identify, consummate and successfully integrate acquisitions (including the
acquisition of Cephalon), the effects of increased leverage as a result of the
acquisition of Cephalon, the extent to which any manufacturing or quality
control problems damage our reputation for high quality production and require
costly remediation, our potential exposure to product liability claims to the
extent not covered by insurance, increased government scrutiny in both the
U.S. and Europe of our agreements with brand companies, potential liability
for sales of generic products prior to a final resolution of outstanding
patent litigation, including that relating to the generic version of
Protonix®, our exposure to currency fluctuations and restrictions as well as
credit risks, the effects of reforms in healthcare regulation and
pharmaceutical pricing and reimbursement, any failures to comply with complex
Medicare and Medicaid reporting and payment obligations, governmental
investigations into sales and marketing practices (particularly for our
specialty pharmaceutical products), uncertainties surrounding the legislative
and regulatory pathway for the registration and approval of
biotechnology-based products, adverse effects of political or economical
instability, major hostilities or acts of terrorism on our significant
worldwide operations, interruptions in our supply chain or problems with our
information technology systems that adversely affect our complex manufacturing
processes, any failure to retain key personnel (including Cephalon employees)
or to attract additional executive and managerial talent, the impact of
continuing consolidation of our distributors and customers, variations in
patent laws that may adversely affect our ability to manufacture our products
in the most efficient manner, potentially significant impairments of
intangible assets and goodwill, potential increases in tax liabilities, the
termination or expiration of governmental programs or tax benefits,
environmental risks and other factors that are discussed in our Annual Report
on Form 20-F for the year ended December 31, 2011 and in our other filings
with the U.S. Securities and Exchange Commission. Forward-looking statements
speak only as of the date on which they are made and the Company undertakes no
obligation to update or revise any forward-looking statement, whether as a
result of new information, future events or otherwise.
Contact:
Teva Pharmaceutical Industries Ltd.
IR:
United States
Kevin C. Mannix, 215-591-8912
or
Kristen Frank, 215-591-8908
or
Israel
Tomer Amitai, 972-3-926-7656
or
PR:
Israel
Hadar Vismunski-Weinberg, 972-3-926-7687
or
United States
Denise Bradley, 215-591-8974